{
    "clinical_study": {
        "@rank": "97393", 
        "arm_group": [
            {
                "arm_group_label": "Pneumostem\u00ae", 
                "arm_group_type": "Experimental", 
                "description": "A single intratracheal administration of Pneumostem\u00ae (1.0 x 10^7 cells/kg)"
            }, 
            {
                "arm_group_label": "normal saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "A single intratracheal administration of normal saline"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the efficacy and safety of a single intratracheal\n      administration of Pneumostem\u00ae for treatment of Bronchopulmonary Dysplasia (BPD) in high-risk\n      premature infants by comparing Pneumostem-treated group with a control group."
        }, 
        "brief_title": "Efficacy and Safety Evaluation of Pneumostem\u00ae Versus a Control Group for Treatment of BPD in Premature Infants", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Bronchopulmonary Dysplasia", 
        "condition_browse": {
            "mesh_term": "Bronchopulmonary Dysplasia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 5 - 14 days since birth\n\n          -  Fetal gestational age: \u226523 weeks and <29 weeks\n\n          -  Birth weight: \u2265500g and \u22641250g\n\n          -  Premature infant of equal to or less than 2 weeks of age who is receiving a\n             ventilator therapy at a rate of > 12 breath/min and > 25% oxygen\n\n          -  Patient whose ventilator setting has not been changed and who has shown aggravation\n             of the illness within the 24 hours prior to the study enrollment\n\n          -  Patient with a written consent form signed by a legal representative or a parent upon\n             explanation of the clinical trial\n\n        Exclusion Criteria:\n\n          -  Patient with  concurrent cyanotic or acyanotic congenital heart diseases, except for\n             patent ductus arteriosus\n\n          -  Patient with a concurrent severe lung malformation (i.e. Pulmonary hypoplasia,\n             congenital diaphragmatic hernia, congenital cystic lung disease)\n\n          -  Patient with a concurrent severe lung malformation with chromosome anomalies (i.e.\n             Edward syndrome, Patau syndrome, Down syndrome, etc) or severe congenital\n             malformation (Hydrocephalus, Encephalocele, etc)\n\n          -  Patient with a concurrent severe congenital infection (i.e. Herpes, Toxoplasmosis,\n             Rubella, Syphilis, AIDS, etc)\n\n          -  Patient withCRP > 30 mg/dL; Severe sepsis or shock\n\n          -  Patient who is scheduled for or expected to undergo a surgical procedure 72 hours\n             prior to/following the administration of the study drug\n\n          -  Patient who has been administered with a surfactant within the 24 hours prior to the\n             administration of the study drug\n\n          -  Patient with severe intracranial hemorrhage \u2265 grade 3 or 4\n\n          -  Patient with active pulmonary hemorrhage or active air leak syndrome at the time of\n             screening\n\n          -  Patient with a history of participating in other clinical studies\n\n          -  Patient who is allergic to Gentamicin\n\n          -  Patient who is considered inappropriate to participate in the study by the\n             investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "14 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828957", 
            "org_study_id": "MP-CR-009"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pneumostem\u00ae", 
                "intervention_name": "Pneumostem\u00ae", 
                "intervention_type": "Biological", 
                "other_name": "Human umbilical cord blood-derived mesenchymal stem cells"
            }, 
            {
                "arm_group_label": "normal saline", 
                "intervention_name": "Normal Saline", 
                "intervention_type": "Other", 
                "other_name": "Normal Saline"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Human Umbilical Cord Blood Derived Mesenchymal Stem Cells", 
            "Bronchopulmonary dysplasia", 
            "Premature infants"
        ], 
        "lastchanged_date": "November 1, 2013", 
        "link": {
            "url": "http://clinicaltrials.gov/ct2/show/NCT01297205?term=medipost&rank=2"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Won-Soon Park, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Yoon-Sil Jang, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ai-Rhan Kim, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-blind, Multi-center, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Pneumostem\u00ae Versus a Control Group for Treatment of Bronchopulmonary Dysplasia in Premature Infants", 
        "overall_contact": {
            "email": "wioh@medi-post.co.kr", 
            "last_name": "Wonil Oh, MD, PhD", 
            "phone": "+82-2-3465-6670"
        }, 
        "overall_official": [
            {
                "affiliation": "Department of Pediatrics, Samsung Medical Center", 
                "last_name": "Won-Soon Park, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Department of Neonatology, Asan Medical Center", 
                "last_name": "Ai-Rhan Kim", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence of BPD (moderate to severe) or mortality rate at 36 weeks PMA", 
            "measure": "Incidence of BPD (moderate to severe) or mortality at 36 weeks PMA", 
            "safety_issue": "No", 
            "time_frame": "36 weeks PMA"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828957"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Intubation duration", 
                "safety_issue": "No", 
                "time_frame": "36 weeks PMA"
            }, 
            {
                "measure": "Incidence of BPD", 
                "safety_issue": "No", 
                "time_frame": "28-days since birth"
            }, 
            {
                "measure": "Survival rate", 
                "safety_issue": "No", 
                "time_frame": "28-days since birth, 36 weeks PMA, and termination of the trial"
            }, 
            {
                "measure": "Duration of ventilator dependence", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Duration of CPAP treatment", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Postnatal steroid use (%) for the purpose of ventilator weaning", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Cumulative duration of oxygen use", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Incidence of Retinopathy of Prematurity (ROP) of Grade III or more", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Retinopathy of Prematurity (ROP) that require treatment with avastin or laser", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Growth velocity (Z-score)", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Length of stay prior to the first discharge from the hospital", 
                "safety_issue": "No", 
                "time_frame": "duration of the hospital stay, an expected average of approximately 3 months since birth"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Clinically significant laboratory findings", 
                "safety_issue": "Yes", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Incidence of pneumothorax that require intubation", 
                "safety_issue": "Yes", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Incidence of moderate to severe pulmonary hemorrhage", 
                "safety_issue": "Yes", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Incidence of intraventricular hemorrhage of grade 3 or more", 
                "safety_issue": "Yes", 
                "time_frame": "Week 24"
            }
        ], 
        "source": "Medipost Co Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medipost Co Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}